跳至主要内容
临床试验/NCT00772824
NCT00772824已完成4 期

Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients- A Prospective, Randomised, Single Blind, Three Arm, Phase Four Prevention Trial

Banaras Hindu University2 个研究点 分布在 1 个国家目标入组 23 人开始时间: 2007年12月最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
已完成
入组人数
23
试验地点
2
主要终点
Reduction in toxicity

研究概览

简要总结

Glutamine, a non essential branched chain amino acid, is most important non toxic nitrogen carrier in body. It participates in variety of physiological functions. It is a major fuel source of enterocytes and is a substrate for gluconeogenesis in kidney, lymphocytes, and monocytes. It is also a nutrient in muscle protein metabolism in response to infection, inflammation and muscle trauma. The significance of glutamine to metabolic homeostasis becomes evident during periods of stress, when it becomes a conditionally essential amino acid. Role of glutamine as protective agent in hepato-biliary dysfunction, in maintaining mucosal integrity of the Gastrointestinal tract following its administration in patient with major bowel surgery as a supplement and part of TPN in critically ill patients and in patients of septicemia, is well established. However the role of glutamine supplementation in reducing or preventing chemotherapeutic agents induced toxicity in cancer patients is controversial.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • The patients > 18 years of age
  • Histologically or cytologically proven breast cancer
  • Receiving CEF chemotherapy cycles presently or in the past
  • The patients who will give informed consent to participate in the study
  • Patients must have sufficient organ and marrow function
  • Stage 1 neuropathy, subclinical neuropathy, surgery induced neuropathy

排除标准

  • Pregnancy
  • Clinical/biochemical severe liver failure
  • Clinical/biochemical severe renal dysfunction
  • Refusal to participate in the study
  • Patients who have received prior chemotherapy with paclitaxel.
  • Patients who have neuropathy due to any known systemic or metabolic causes like diabetes, leprosy, nutritional deficiency induced (vit. B12) etc

研究组 & 干预措施

2

Active Comparator

Intravenous glutamine

干预措施: IV Glutamine (Dietary Supplement)

1

No Intervention

10 patients (30 cycles) of chemotherapy will receive placebo

3

Experimental

Oral Glutamine

干预措施: Glutamine (Dietary Supplement)

结局指标

主要结局

Reduction in toxicity

时间窗: 3 weeks

次要结局

  • Serum level of creatinine kinase and LDH(3 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Manoj Pandey

Professor, Surgical Oncology

Banaras Hindu University

研究点 (2)

Loading locations...

相似试验

Study of the Effect of Glutamine Supplementation on... | 临床试验